Literature DB >> 31648337

Role of the coagulation system in the pathogenesis of sickle cell disease.

Md Nasimuzzaman1,2, Punam Malik1,2.   

Abstract

Sickle cell disease (SCD) is an inherited monogenic red blood cell disorder affecting millions worldwide. SCD causes vascular occlusions, chronic hemolytic anemia, and cumulative organ damage such as nephropathy, pulmonary hypertension, pathologic heart remodeling, and liver necrosis. Coagulation system activation, a conspicuous feature of SCD that causes chronic inflammation, is an important component of SCD pathophysiology. The key coagulation factor, thrombin (factor IIa [FIIa]), is both a central protease in hemostasis and thrombosis and a key modifier of inflammation. Pharmacologic or genetic reduction of circulating prothrombin in Berkeley sickle mice significantly improves survival, ameliorates vascular inflammation, and results in markedly reduced end-organ damage. Accordingly, factors both upstream and downstream of thrombin, such as the tissue factor-FX complex, fibrinogen, platelets, von Willebrand factor, FXII, high-molecular-weight kininogen, etc, also play important roles in SCD pathogenesis. In this review, we discuss the various aspects of coagulation system activation and their roles in the pathophysiology of SCD.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31648337      PMCID: PMC6849940          DOI: 10.1182/bloodadvances.2019000193

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  133 in total

1.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

2.  Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Pichika Chantrathammachart; Jacqueline Mickelson; Joanne van Ryn; Robert P Hebbel; Dougald M Monroe; Nigel Mackman; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

3.  Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia.

Authors:  D P Inwald; F J Kirkham; M J Peters; R Lane; A Wade; J P Evans; N J Klein
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

4.  Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin.

Authors:  Anna Solovey; Rahn Kollander; Arun Shet; Liming C Milbauer; Stephana Choong; Angela Panoskaltsis-Mortari; Bruce R Blazar; Robert J Kelm; Robert P Hebbel
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

5.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

Review 6.  von Willebrand factor and von Willebrand disease.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

7.  Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1.

Authors:  Antonella Naldini; Annalisa Pucci; Darrell H Carney; Giuseppe Fanetti; Fabio Carraro
Journal:  Cytokine       Date:  2002-12-07       Impact factor: 3.861

8.  Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.

Authors:  Nancy J Roszell; Mary Jo Danton; Maorong Jiang; David Witte; Cynthia Daugherty; Timothy Grimes; Benjamin Girdler; Kathleen P Anderson; Robert S Franco; Jay L Degen; Clinton H Joiner
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

Review 9.  Pathophysiology of stroke in sickle cell disease.

Authors:  Cheryl A Hillery; Julie A Panepinto
Journal:  Microcirculation       Date:  2004-03       Impact factor: 2.628

10.  A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Authors:  Matthew M Heeney; Carolyn C Hoppe; Miguel R Abboud; Baba Inusa; Julie Kanter; Bernhards Ogutu; Patricia B Brown; Lori E Heath; Joseph A Jakubowski; Chunmei Zhou; Dmitry Zamoryakhin; Tsiri Agbenyega; Raffaella Colombatti; Hoda M Hassab; Videlis N Nduba; Janet N Oyieko; Nancy Robitaille; Catherine I Segbefia; David C Rees
Journal:  N Engl J Med       Date:  2015-12-08       Impact factor: 91.245

View more
  9 in total

1.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

2.  A mutant fibrinogen that is unable to form fibrin can improve renal phenotype in mice with sickle cell anemia.

Authors:  Marilou G Narciso; Blair Hoeting; Jeanne M James; Katherine VandenHeuvel; Md Nasimuzzaman
Journal:  EJHaem       Date:  2021-06-15

Review 3.  Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.

Authors:  Maria A Lizarralde-Iragorri; Arun S Shet
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

4.  ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease.

Authors:  Julien Demagny; Aurélie Driss; Alain Stepanian; Nadia Anguel; Louis Affo; Damien Roux; Anoosha Habibi; Sandrine Benghezal; Sophie Capdenat; Paul Coppo; Françoise Driss; Agnès Veyradier
Journal:  Res Pract Thromb Haemost       Date:  2020-12-18

Review 5.  Linking Labile Heme with Thrombosis.

Authors:  Marie-Thérèse Hopp; Diana Imhof
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

Review 6.  Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines.

Authors:  Mohamed S Abdel-Bakky; Elham Amin; Mohamed G Ewees; Nesreen I Mahmoud; Hamdoon A Mohammed; Waleed M Altowayan; Ahmed A H Abdellatif
Journal:  Viruses       Date:  2022-01-24       Impact factor: 5.048

7.  The endothelial glycocalyx in critical illness: A pediatric perspective.

Authors:  Robert P Richter; Gregory A Payne; Namasivayam Ambalavanan; Amit Gaggar; Jillian R Richter
Journal:  Matrix Biol Plus       Date:  2022-03-09

8.  Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia.

Authors:  André Rolim Belisário; Franciane Mendes-Oliveira; Valquíria Reis de Souza; Eduarda Bolina-Santos; Fabíola Gomes Mendes; Elizabeth Castro Moreno; Alice Timponi Franca; Ester Cerdeira Sabino; Dayane Andriotti Otta; Elaine Speziali de Faria; Jordana Grazziela Alves Coelho-Dos-Reis; Olindo Assis Martins-Filho; Anna Bárbara Carneiro-Proietti
Journal:  Hematol Transfus Cell Ther       Date:  2020-12-05

9.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.